Skip to main content

Table 2 Demographic and Clinical Characteristics of Infants for Retinopathy of Prematurity Screening between 2019 and 2020 from February to October

From: The safety and feasibility of the screening for retinopathy of prematurity assisted by telemedicine network during COVID-19 pandemic in Wuhan, China

Demographic and clinical characteristics

Screening assisted by telemedicine network in 2020 No. (%)(N = 267)

Usual screening in 2019 No. (%)(N = 653)

P value

Male

149 (55.8)

375 (57.4)

0.652c

Gestational age, median (IQR), weeks

32 (30 to 34)

33 (31 to 34)

<0.001d

Birth weight, median (IQR),g

1780 (1460 to 2100)

1900 (1510 to 2300)

0.001d

Birth weight group, g

0.003c

 <1500

72 (27.0)

136 (20.8)

0.043c

 1500 to <2000

103 (38.6)

214 (32.8)

0.093c

  ≥ 2000

92 (34.5)

303 (46.4)

0.001c

Ocular findings

 Total

25 (9.4)

48 (7.4)

0.305c

 Zone III Phase 1

12 (4.5)

35 (5.4)

0.588c

 Zone III Phase 2

3 (1.1)

1 (0.2)

0.076b

 Zone II Phase 1

1 (0.4)

1 (0.2)

0.496b

 Zone II Phase 2

1 (0.4)

5 (0.8)

0.678b

 Zone II Phase 2 Plus

1 (0.4)

2 (0.3)

>0.99b

 CMV retinitis

3 (1.1)

1 (0.2)

0.076b

 Retina hemorrhage

3 (1.1)

3 (0.5)

0.364b

 Optic disc dysplasia

1 (0.4)

 Traffic (come from other cities)

154 (57.7)

NA

  1. ROP: Retinopathy of Prematurity; CMV: Cytomegalovirus; NA: not available
  2. b Fisher’s exact probability test
  3. c: χ2 Test
  4. d: Mann-Whitney U test